CRIS Current Research Information System

PILERI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.915
AS - Asia 17.018
EU - Europa 14.435
SA - Sud America 1.165
AF - Africa 1.002
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 24
Totale 55.587
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.712
SG - Singapore 4.662
CN - Cina 4.611
GB - Regno Unito 4.198
VN - Vietnam 4.184
DE - Germania 1.924
IT - Italia 1.720
SE - Svezia 1.600
HK - Hong Kong 1.077
FR - Francia 1.070
UA - Ucraina 1.032
IN - India 985
RU - Federazione Russa 902
BR - Brasile 845
IE - Irlanda 498
ZA - Sudafrica 418
JP - Giappone 332
EE - Estonia 300
KR - Corea 288
CH - Svizzera 230
NL - Olanda 198
FI - Finlandia 197
CI - Costa d'Avorio 194
AR - Argentina 141
TG - Togo 140
CA - Canada 106
SC - Seychelles 87
PH - Filippine 86
JO - Giordania 82
BD - Bangladesh 80
HR - Croazia 73
ID - Indonesia 72
BE - Belgio 71
TR - Turchia 70
TH - Thailandia 69
GR - Grecia 68
BG - Bulgaria 65
MX - Messico 62
IQ - Iraq 60
IR - Iran 57
AT - Austria 56
PK - Pakistan 52
TW - Taiwan 49
PL - Polonia 47
LB - Libano 46
NG - Nigeria 46
EC - Ecuador 44
ES - Italia 40
CL - Cile 36
SA - Arabia Saudita 31
UZ - Uzbekistan 31
CO - Colombia 30
LU - Lussemburgo 30
LT - Lituania 21
EG - Egitto 20
MY - Malesia 20
TN - Tunisia 20
PY - Paraguay 18
VE - Venezuela 18
EU - Europa 17
AU - Australia 14
MA - Marocco 14
PE - Perù 14
RO - Romania 14
UY - Uruguay 13
DZ - Algeria 12
KE - Kenya 12
AE - Emirati Arabi Uniti 11
CZ - Repubblica Ceca 11
ET - Etiopia 11
AL - Albania 10
DO - Repubblica Dominicana 10
NZ - Nuova Zelanda 10
PT - Portogallo 10
IL - Israele 9
OM - Oman 9
HU - Ungheria 8
DK - Danimarca 7
SK - Slovacchia (Repubblica Slovacca) 7
BO - Bolivia 6
KG - Kirghizistan 6
RS - Serbia 6
A2 - ???statistics.table.value.countryCode.A2??? 5
CR - Costa Rica 5
NP - Nepal 5
AO - Angola 4
AZ - Azerbaigian 4
GE - Georgia 4
HN - Honduras 4
KZ - Kazakistan 4
PS - Palestinian Territory 4
SI - Slovenia 4
BA - Bosnia-Erzegovina 3
GH - Ghana 3
IS - Islanda 3
JM - Giamaica 3
KH - Cambogia 3
KW - Kuwait 3
NO - Norvegia 3
SY - Repubblica araba siriana 3
Totale 55.529
Salva come PNG Salva come JPEG
Città #
Southend 3.699
Singapore 3.066
Fairfield 2.741
Ashburn 1.963
Woodbridge 1.379
Chandler 1.266
Houston 1.257
Seattle 1.203
Wilmington 1.201
Hong Kong 1.016
Cambridge 981
San Jose 957
Princeton 882
Ho Chi Minh City 825
Ann Arbor 813
Dong Ket 694
Hanoi 684
Jacksonville 639
Hefei 627
Santa Clara 555
Boardman 499
Dublin 496
Beijing 474
Lauterbourg 425
Nanjing 420
Westminster 382
Padova 374
Tokyo 297
Los Angeles 296
Bologna 246
Seoul 240
Berlin 227
Saint Petersburg 204
Buffalo 199
Jinan 196
New York 195
Abidjan 193
Bern 192
Milan 187
Helsinki 171
Shenyang 169
Mülheim 146
Nanchang 144
San Diego 142
Lomé 139
Hebei 133
Changsha 121
Haiphong 114
Tianjin 114
Bremen 112
Da Nang 108
Dallas 102
Frankfurt am Main 98
Guangzhou 97
São Paulo 94
Redondo Beach 91
Jiaxing 88
Zhengzhou 86
Amman 81
Hangzhou 79
Chicago 75
Shanghai 75
Medford 71
Mahé 69
The Dalles 66
Brussels 63
Sofia 62
Bengaluru 60
Dearborn 60
Turin 60
Ningbo 57
Phoenix 56
Hyderabad 55
Munich 55
Norwalk 55
Taizhou 55
Redwood City 54
Council Bluffs 51
Falls Church 50
Haikou 49
Olalla 49
Rome 49
San Venanzo 49
Yubileyny 49
Taiyuan 47
Des Moines 46
Johannesburg 46
London 43
Abeokuta 42
Toronto 42
Verona 42
Redmond 40
Hải Dương 39
Nuremberg 39
Can Tho 37
Biên Hòa 34
Lanzhou 34
Wuhan 34
Montreal 33
Orem 31
Totale 36.642
Salva come PNG Salva come JPEG
Nome #
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 318
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. 283
Biology and treatment of follicular lymphoma. 277
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens 277
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. 266
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target 263
CD103 marks a subset of human CD34+-derived langerin+ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1 256
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 252
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 251
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. 250
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 248
Prevention of large-scale implementation of unnecessary and expensive predictive tests in Hodgkin's lymphoma – Authors' reply 247
Effectiveness of Fludarabine, Idarubicin and Cyclophosphade (FLUIC) Combination Regimen for Young Patients with Untreated Non-Follicular Low-Grade Non-Hodgkin’s Lymphoma. 246
B-cells and mixed cryoglobulinemia. 242
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. 241
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 240
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 240
B-cell non-Hodgkin lymphomas in Uganda: an immunohistochemical appraisal on tissue microarray. 233
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
IFI16 expression is related to selected transcription factors during B-cell differentiation 227
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 226
T-Cell Lymphomas in South America and Europe 223
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 220
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 217
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 217
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 217
Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. 216
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 216
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. 214
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 212
High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience 210
Expression of CD52 in peripheral T-cell lymphoma. 208
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 207
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 207
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 206
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 206
Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change 204
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 201
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 197
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 196
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma 196
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 194
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 193
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. 192
Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. 191
CD30 expression in peripheral T-cell lymphomas 191
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. 190
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 189
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 188
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 188
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 187
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 186
Histopathology of B-cell chronic lymphocytic leukemia. 186
Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of Follicular dendritic cell sarcomas 186
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 185
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 185
Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. 184
Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease. 183
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 183
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 183
A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. 182
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 182
Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. 181
Anaplastic Large Cell Lymphoma: a critical reappraisal 180
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 179
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 179
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 179
BCL10 down-regulation in peripheral T-cell lymphomas. 178
Tumor protein D52 (TPD52): a novel B-cell/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI. 178
Pathobiology of hodgkin lymphoma. 177
CDK9/Cyclin T1 expression during normal lymphoid differentiation and malignant transformation. 175
Pitfalls in diagnosis: primary mediastinal non-seminomatous germ cell tumour with bone marrow metastasis showing melanoma-like phenotype. 174
BCL10 expression in peripheral T-Cell lymphoma not otherwise specified. 174
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary - Neoplasia a cellule dendritiche plasmocitoidi blastiche: il santuario cutaneo 173
Small bowel obstruction caused by a large B-cell lymphoma in a patient with multicentric Castleman’s disease: an unusual occurrence 173
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 173
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 172
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 172
Enteropathy-associated T-cell lymphoma. 172
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 172
Molecular profiling of aggressive lymphomas 171
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 171
Aberrant promoter methylation of multiple genes thoughout the clinico-pathologic spectrum of B-cell neoplastia. 170
The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma 170
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 168
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 168
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 168
WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. 168
Pathobiology of anaplastic large cell lymphoma. 167
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 167
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 167
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 166
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 165
Molecular genetics of peripheral T-cell lymphomas 165
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 164
A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp. 163
Familial haemophagocytic lymphohistiocytosis-related plasma cell neoplasm: a case report. 162
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 162
Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma 162
Totale 19.956
Salva come PNG Salva come JPEG
Categoria #
all - tutte 148.891
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 148.891
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.102 0 0 0 0 0 0 0 0 0 286 259 1.557
2021/20226.593 706 232 540 573 677 381 142 449 247 394 1.258 994
2022/20236.393 847 864 353 789 458 472 221 332 1.011 174 504 368
2023/20241.590 89 290 108 174 142 290 109 94 48 128 54 64
2024/20256.621 217 1.297 583 463 1.044 373 562 158 71 330 251 1.272
2025/202614.518 1.043 1.619 1.650 1.322 1.853 982 1.366 733 3.026 924 0 0
Totale 56.382